Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
274,772,727
-
Total 13F shares
-
167,381,791
-
Share change
-
+11,306,475
-
Total reported value
-
$289,604,775
-
Put/Call ratio
-
16%
-
Price per share
-
$1.73
-
Number of holders
-
126
-
Value change
-
+$18,983,312
-
Number of buys
-
66
-
Number of sells
-
42
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q4 2024
As of 31 Dec 2024 Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) had 126 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 167,381,791 shares of stock of the company.
Largest 10 holders included Avoro Capital Advisors LLC, MORGAN STANLEY, FMR LLC, BlackRock, Inc., RA CAPITAL MANAGEMENT, L.P., Octagon Capital Advisors LP, VANGUARD GROUP INC, RTW INVESTMENTS, LP, Siren, L.L.C., and STATE STREET CORP.
This table shows 126 institutional shareholders of the security as of 31 Dec 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.